In case of threatening preterm birth, it is standard to recommend treatment with betamethasone to accelerate fetal lung maturation. In pregnant women with diabetes, treatment with betamethasone can lead to significant hyperglycemia, which may cause hypoglycemia in the neonate. Changes in blood glucose in non-diabetic women are less investigated. In this study we aim to examine changes in maternal blood glucose levels in non-diabetic women, during treatment with betamethasone, by continuous glucose monitoring.
Hypotheses:
Administration of betamethasone induce significant hyperglycemia in non-diabetic pregnant women during treatment.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth:
* Premature contractions and shortening of the cervix, or
* Preterm premature rupture of membranes.
* Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion)
* Age over 18 years
* Read and understand Danish
Exclusion Criteria:
* Multiple pregnancy
* Diabetes
* Pre-existing maternal use of medications that affect glucose metabolism
Primary outcome measure(s)
Maternal blood glucose levels before, under and after the administration of betamethasone — 7-14 days Blood glucose levels (mmol/L) will be measured continuously using a continuous glucose monitor including a small electrode under the skin
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.